ANIK Anika Therapeutics Inc

Price (delayed)

$40.41

Market cap

$582.83M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.9

Enterprise value

$505.73M

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Anika Therapeutics partners with clinicians to understand what they need ...

Highlights
Anika Therapeutics's debt has shrunk by 72% YoY and by 2.3% QoQ
The net income has surged by 53% since the previous quarter
Anika Therapeutics's quick ratio has decreased by 49% YoY but it has increased by 19% from the previous quarter
Anika Therapeutics's gross margin has decreased by 13% YoY but it has increased by 4.3% from the previous quarter

Key stats

What are the main financial stats of ANIK
Market
Shares outstanding
14.42M
Market cap
$582.83M
Enterprise value
$505.73M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.03
Price to sales (P/S)
4.25
EV/EBIT
N/A
EV/EBITDA
5,682.4
EV/Sales
3.7
Earnings
Revenue
$136.82M
EBIT
-$15.65M
EBITDA
$89,000
Free cash flow
$6.86M
Per share
EPS
-$0.9
Free cash flow per share
$0.48
Book value per share
$19.93
Revenue per share
$9.51
TBVPS
$18.61
Balance sheet
Total assets
$363.13M
Total liabilities
$76.33M
Debt
$20.08M
Equity
$286.8M
Working capital
$136.39M
Liquidity
Debt to equity
0.07
Current ratio
4.3
Quick ratio
3.06
Net debt/EBITDA
-866.3
Margins
EBITDA margin
0.1%
Gross margin
55.5%
Net margin
-9.3%
Operating margin
-30.9%
Efficiency
Return on assets
-3.4%
Return on equity
-4.5%
Return on invested capital
-9.7%
Return on capital employed
-4.9%
Return on sales
-11.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANIK stock price

How has the Anika Therapeutics stock price performed over time
Intraday
1.99%
1 week
3.38%
1 month
-4.15%
1 year
18.09%
YTD
-10.72%
QTD
-6.65%

Financial performance

How have Anika Therapeutics's revenue and profit performed over time
Revenue
$136.82M
Gross profit
$75.87M
Operating income
-$42.25M
Net income
-$12.7M
Gross margin
55.5%
Net margin
-9.3%
Anika Therapeutics's net margin has surged by 55% QoQ
The net income has surged by 53% since the previous quarter
Anika Therapeutics's gross margin has decreased by 13% YoY but it has increased by 4.3% from the previous quarter
The company's gross profit rose by 10% QoQ but it fell by 4.9% YoY

Growth

What is Anika Therapeutics's growth rate over time

Valuation

What is Anika Therapeutics stock price valuation
P/E
N/A
P/B
2.03
P/S
4.25
EV/EBIT
N/A
EV/EBITDA
5,682.4
EV/Sales
3.7
The company's EPS has surged by 52% QoQ
ANIK's price to book (P/B) is 17% less than its 5-year quarterly average of 2.4 and 5% less than its last 4 quarters average of 2.1
ANIK's equity is up by 3.7% since the previous quarter
ANIK's P/S is 24% below its 5-year quarterly average of 5.5 and 7% below its last 4 quarters average of 4.5
The revenue has grown by 9% YoY and by 6% from the previous quarter

Efficiency

How efficient is Anika Therapeutics business performance
The company's return on sales has surged by 57% QoQ
Anika Therapeutics's ROE has soared by 53% from the previous quarter
The return on assets has surged by 50% since the previous quarter
The ROIC is up by 48% since the previous quarter

Dividends

What is ANIK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIK.

Financial health

How did Anika Therapeutics financials performed over time
Anika Therapeutics's total liabilities has decreased by 50% YoY and by 11% from the previous quarter
Anika Therapeutics's quick ratio has decreased by 49% YoY but it has increased by 19% from the previous quarter
Anika Therapeutics's debt is 93% lower than its equity
Anika Therapeutics's debt has shrunk by 72% YoY and by 2.3% QoQ
The debt to equity has dropped by 72% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.